期刊文献+

CYP2C19基因多态性对氯吡格雷代谢的影响 被引量:5

原文传递
导出
摘要 缺血性心脏病、脑卒中、下呼吸道感染、慢性阻塞性肺病是世界范围内的主要健康问题。据世界卫生组织(WHO)2015统计,全球约有1750万人死于心血管疾病,占总死亡人数的31%。氯吡格雷作为抗血小板聚集药物已广泛应用于临床心血管疾病患者的二级预防及治疗。研究发现CYP2C19基因具有遗传多态现象,其不同表型对氯吡格雷药物代谢具有重要影响,甚至发生氯吡格雷抵抗,从而增加患者再发心血管事件的概率。本研究对CYP2C19基因多态性及CYP2C19主要多态性位点对氯吡格雷代谢的影响作一综述。
作者 刘欣 吉维忠
出处 《卒中与神经疾病》 2018年第4期475-478,共4页 Stroke and Nervous Diseases
  • 相关文献

参考文献3

二级参考文献75

  • 1Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of ath-erosclerotic cardiovascular disease. Nat Rev Drug Discovy 2005,4(3):193-205.
  • 2Yusuf S, Ounpuu S,Anand S. The global epidemic of atheroscleroticcardiovascular disease. Med Principles PracU 2002,1 l(suppl 2): 3-8.
  • 3Gasparyan AY. Aspirin and clopidogrel resistance: methodologicalchallenges and opportunities. Vase Health Risk Managy 2010,6: 109-112.
  • 4KimKA, Park PW, Hong SJ, et al. The effect of CYP2C19 poly-morphism on the pharmacokinetics and pharmacodynamics ofclopidogrel: a possible mechanism for clopidogrel resistance. ClinPharmacol Ther, 2008,84(2): 236-242.
  • 5Soft F, Giusti B, Marcucci R, et al Cytochrome P450 2C19*2 poly-morphism and cardiovascular recurrences in patients taking clopi-dogrel: a meta-analysis. Pharmacogenomics /, 2011,11(3): 199-206.
  • 6Wells G, Shea B, O'Connell D, et al. New Castle-Ottawa Quality As-sessment Scale—Cohort Studies. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Assessed on June 15,2012.
  • 7Mega JL,Simon T, Collet JP, et al. Reduced-fixnction CYP2C19 gen-otype and risk of adverse clinical outcomes among patients treatedwith clopidogrel predominantly for PCI: a meta-analysis. JAMA,2010,304(16): 1821-1830.
  • 8Hulot JS, Collet JP, Silvain J. et al. Cardiovascular risk in dopidog-rel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: asystematic meta-analysis. / Am Coll Cardioh 2010, 56(2): 134-143.
  • 9Higgins JPT, Green S. The Cochrane Collaboration,s tool for as-sessing risk of bias. Cochrane Handbook for Systematic Reviews ofInterventions Version 5.1.0: Section 8. The Cochrane Collaboration.Available at: www.cochrane-handbook.org. Assessed on September1,2013.
  • 10Bhatt DL, Pare G, Eikelboom JW, et al. The relationship betweenCYP2C19 polymorphisms and ischaemic and bleeding outcomesin stable outpatients: the CHARISMA genetics study. Eur Heart /,2012,33(17):2143-2150.

共引文献37

同被引文献56

引证文献5

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部